Filing Analysis
Vaxart, Inc. announced the formation of two new Board committees: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee. The filing also details the appointment of committee members and mentions an anticipated future director appointment per a prior Cooperation Agreement.
🚩 Red Flags
- The mention of a 'Cooperation Agreement' dated July 1, 2026, regarding the appointment of a director often suggests external pressure or influence from a significant shareholder/activist investor.
📋 Key Facts
- Formed the Clinical and Regulatory Affairs Committee to oversee research, clinical, and regulatory programs.
- Appointed James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D. to the Clinical and Regulatory Affairs Committee.
- Formed the Stockholder Engagement Committee to oversee relations with stockholders.
- Appointed W. Mark Watson (Interim Chair) and Steven Lo to the Stockholder Engagement Committee.
- Anticipates appointing a new director in the future to serve as Chair of the Stockholder Engagement Committee pursuant to a July 1, 2026 Cooperation Agreement.
Vaxart, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the release of quarterly earnings via press release.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing financial results.
- The filing is furnished under Item 2.02 of Form 8-K.
Vaxart, Inc. reported the results of its 2026 annual meeting of stockholders held on July 16, 2026. The company successfully elected six directors and ratified its independent auditor, but failed to secure a non-binding advisory approval for executive compensation.
🚩 Red Flags
- Shareholder dissatisfaction expressed through the rejection of 'Say on Pay' (Proposal 3), where a majority voted against executive compensation.
📋 Key Facts
- Annual Meeting held on July 16, 2026, with a quorum representing approximately 45.7% of outstanding shares.
- Six nominees were elected to the Board of Directors (Breitmeyer, Finney, Heron, Lo, Watson, and Wheadon).
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders voted against the non-binding advisory proposal regarding executive compensation (46,024,068 votes For vs. 51,842,781 votes Against).
Vaxart, Inc. announced positive topline 12-month safety data from its Phase 2b clinical trial for an oral pill COVID-19 vaccine candidate. The study involved approximately 400 participants and showed no vaccine-related serious adverse events (SAEs) compared to an mRNA comparator.
📋 Key Facts
- Topline 12-month safety data released on July 6, 2026.
- Phase 2b clinical trial evaluated oral pill COVID-19 vaccine against an approved mRNA vaccine comparator.
- Study cohort consisted of approximately 400 participants.
- No vaccine-related serious adverse events (SAEs) reported in either study arm.
- No sustained Grade 3 or higher adverse events reported.
Vaxart, Inc. entered into a Cooperation Agreement with a group of stockholders to resolve a proxy contest and demand for books and records. The agreement involves the withdrawal of director nominations in exchange for the appointment of a new independent director and several governance reforms.
🚩 Red Flags
- Resolution of a proxy contest/activist shareholder dispute indicates significant internal friction and governance instability.
- The company is incurring non-operating costs (up to $650,000) to settle the dispute with the Stockholder Group.
📋 Key Facts
- Entered into a Cooperation Agreement on July 1, 2026, with Daniel P. Houle, Mark Silverberg, MD, Matthew M. Wallace, MD, Patrice Raffy, Q3 Nominees Pty Ltd, and Marc Eustace Pereira.
- The Stockholder Group withdrew its notice nominating three director candidates for the 2026 Annual Meeting.
- The Stockholder Group withdrew its demand to inspect certain books and records of the Company.
- A new independent director will be mutually agreed upon and appointed to the Board within 60-90 days following the 2026 Annual Meeting.
- The Board will adopt a resignation policy for uncontested elections receiving less than a majority, stock ownership guidelines for directors, and form two new committees: Clinical and Regulatory Affairs Committee and a Stockholder Engagement Committee.
- Management must meet with the Stockholder Group at least once per fiscal quarter to discuss financial and strategic matters.
- The Company will reimburse the Stockholder Group up to $650,000 for documented out-of-pocket expenses related to their solicitation efforts.
Vaxart, Inc. entered into Modification No. 7 of its BARDA-funded Project Agreement with Advanced Technology International. The modification reflects a significant reduction in total available funding due to a partial termination ordered by BARDA.
🚩 Red Flags
- Significant reduction in total project funding (down ~$116M).
- Partial termination of the agreement by BARDA on August 5, 2025.
- Reduction in clinical trial scope/participant enrollment (approx. 50% decrease).
📋 Key Facts
- Total available funding under the modified agreement is approximately $345 million.
- The modification represents an approximate $116 million decrease from the previous modification amount.
- Funding reduction follows a ~50% reduction in trial participants due to a BARDA partial termination ordered on August 5, 2025.
- The funding includes approximately $68 million in firm fixed price amounts and remaining funds for cost reimbursement.
- Modification allows for the release of approximately $29 million specifically for trial completion and exploratory analyses.
Vaxart, Inc. has entered into a termination agreement to end its headquarters lease at 170 Harbor Way, effective May 15, 2026. This move is part of a broader cost-reduction strategy and will involve relocating operations to existing office space in South San Francisco.
🚩 Red Flags
- Cost-cutting measures often indicate liquidity management needs in micro-cap biotech firms.
📋 Key Facts
- Termination of lease for ~24,606 sq. ft. located at 170 Harbor Way, South San Francisco, CA.
- Lease termination effective date: May 15, 2026 (originally scheduled to expire March 31, 2029).
- No termination fees or penalties required for the early exit.
- Company will relocate headquarters and labs to existing South San Francisco offices.
- The move is explicitly intended as a cost reduction measure.
Vaxart, Inc. filed an 8-K to announce its third quarter 2025 financial results and provide a business update for the period ended September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release titled 'Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results' as Exhibit 99.1.
- The information is furnished but not filed for purposes of Section 18 of the Exchange Act.
Vaxart has entered into a significant exclusive license and collaboration agreement with Dynavax Technologies for its oral COVID-19 vaccine candidate. The deal includes an upfront cash payment of $25 million and a $5 million equity purchase, alongside substantial contingent milestone payments.
🚩 Red Flags
- The equity portion of the deal ($0.45/share) is a direct issuance from a shelf registration, which may result in moderate dilution for existing shareholders.
- Contingent nature of the $50M development fee and subsequent milestones depends entirely on clinical success and Dynavax's discretion.
📋 Key Facts
- Exclusive License Agreement signed with Dynavax Technologies Corporation (Nasdaq: DVAX) on November 4, 2025.
- Dynavax to pay Vaxart a $25 million upfront license fee.
- Dynavax will purchase 11,111,111 shares of VXRT common stock at $0.45 per share (totaling ~$5 million).
- Vaxart must complete its ongoing Phase 2b clinical trial and perform obligations under the Project NextGen/BARDA award.
- Dynavax has the option to assume full development responsibility after EOP2 meeting, which would trigger an additional $50 million fee.
- Potential for up to $195 million in regulatory milestones and $425 million in net sales milestones.
- Vaxart retains rights to its oral delivery platform for all indications other than the licensed coronaviruses.
Vaxart received a follow-up notice from ATI regarding a BARDA-funded Project Agreement, confirming that the scope of work is being conclusively delimited to exclude previously paused activities. While certain project work remains excluded, the company will continue to receive funding for following 5,000 participants already enrolled in its Phase 2b COVID-19 vaccine candidate trial.
🚩 Red Flags
- Continuation of 'Paused Work' status for certain aspects of the BARDA-funded Project Agreement.
- Reduction in project scope from a major government partner (BARDA/ATI).
📋 Key Facts
- Received a 'Follow-Up Notice' from ATI on October 8, 2025, clarifying the scope of Project Agreement No. 01.
- BARDA intends to conclusively delimit the Project Agreement to exclude the previously 'Paused Work'.
- The approximately 5,000 participants already enrolled in the Phase 2b Trial will continue to be followed.
- The Company will continue to receive funding specifically for the evaluation of these enrolled participants.
Vaxart, Inc. has received a formal notice from Nasdaq stating its securities will be delisted following the company's decision to withdraw its proposal for a reverse stock split. This action constitutes a failure to meet the conditions previously set by the Nasdaq Hearings Panel.
🚩 Red Flags
- Delisting notice from a major exchange (Nasdaq).
- Failure to execute a reverse stock split required for compliance with minimum bid price requirements.
- Trading has already been suspended on Nasdaq since July 8, 2025.
- Company is currently relegated to the OTCQX market.
📋 Key Facts
- Nasdaq issued a letter on September 19, 2025, stating securities will be delisted due to noncompliance with Panel Conditions.
- The company withdrew its proposal for a reverse stock split on September 18, 2025, failing the condition to obtain shareholder approval by September 5, 2025.
- Trading on Nasdaq was previously suspended on July 8, 2025.
- Common stock is currently trading on the OTCQX® Best Market under the symbol 'VXRT'.
Vaxart, Inc. has announced the withdrawal of a previously proposed stockholder proposal and will not reconvene its adjourned Special Meeting originally scheduled for September 19, 2025. This follows an earlier adjournment on September 5, 2025, intended to allow stockholders more time to vote.
🚩 Red Flags
- Withdrawal of a stockholder proposal after an adjournment suggests significant difficulty in achieving the required vote/quorum or internal disagreement regarding the direction of the company.
- The failure to pass a special meeting item often indicates underlying governance issues or lack of shareholder support for critical corporate actions.
📋 Key Facts
- The Company determined on September 18, 2025, to withdraw the Proposal from stockholder consideration.
- The reconvened Special Meeting scheduled for September 19, 2025, will no longer take place.
- The original meeting was held on September 5, 2025, and subsequently adjourned to provide more time for voting.
Vaxart, Inc. has adjourned its Special Meeting of stockholders, originally scheduled for September 5, 2025, to allow more time for proxy solicitation. The reconvened meeting is now set for September 19, 2025.
🚩 Red Flags
- Adjournment of a special meeting can sometimes indicate difficulty in reaching the required threshold for a specific proposal (e.g., board composition or structural changes).
📋 Key Facts
- The Special Meeting held on September 5, 2025, was adjourned because the Board believes stockholders need additional time to vote.
- A quorum was present at the initial meeting, with proxies representing approximately 64.25% of outstanding common stock.
- The reconvened Special Meeting is scheduled for Friday, September 19, 2025, at 8:30 a.m. PT via live webcast.
- The record date remains July 29, 2025.
Vaxart, Inc. announced the retirement of Michael J. Ph.D., who serves as Chair of the Board and Chair of the Science and Technology Committee, effective September 30, 2025. The company also noted a reduction in board size from six to five members following his departure.
🚩 Red Flags
- Reduction in board size (from 6 to 5) can sometimes indicate a period of restructuring, though not explicitly stated here.
📋 Key Facts
- Michael J. Finney, Ph.D. is retiring from the Board of Directors effective September 30, 2025.
- Dr. Finney serves as Chair of the Board and Chair/member of the Science and Technology Committee.
- The retirement is for personal reasons and not due to any disagreement with company operations or policies.
- The Board size will be reduced from six members to five members upon his departure.
Vaxart, Inc. has received a decision from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market, contingent upon the company executing a reverse stock split and obtaining shareholder approval.
🚩 Red Flags
- Mandatory reverse stock split required to maintain Nasdaq listing
- Ongoing failure to meet minimum bid price requirements (stock has been below $1.00)
- Risk of immediate delisting if shareholder vote on RSS fails in September 2025
- Nasdaq reserves the right to reconsider terms based on any significant event during the exception period
📋 Key Facts
- Nasdaq Hearing Panel granted an exception to delisting following an appeal of the company's non-compliance with minimum bid price requirements.
- The Company must obtain shareholder approval for a reverse stock split (RSS) by September 5, 2025.
- The Company must complete the RSS on or before October 6, 2025.
- Compliance with the Minimum Bid Price Requirement must be demonstrated by October 17, 2025.
- Failure to obtain shareholder approval for the RSS at the September 5 special meeting will result in delisting.
Vaxart, Inc. held a virtual fireside chat with management on August 20, 2025. The company is furnishing the transcript of this event via Item 7.01.
📋 Key Facts
- Event date: August 20, 2025
- Nature of event: Virtual stockholder fireside chat with management
- Filing type: Regulation FD Disclosure (Item 7.01)
- Transcript provided as Exhibit 99.1
Vaxart, Inc. announced a virtual stockholder fireside chat featuring members of the senior management team scheduled for August 20, 2025.
📋 Key Facts
- Event: Virtual stockholder fireside chat.
- Date/Time: Wednesday, August 20, 2025, at 4:30 p.m. ET.
- Participants: Members of the senior management team.
- Filing Date: August 15, 2025.
Vaxart, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025 and provided a general business update.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2025.
- Issued a press release titled 'Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results'.
- The filing is furnished under Item 2.02 and does not constitute 'filed' information for liability purposes.
Vaxart, Inc. received a stop work order from Advanced Technology International (ATI) regarding its Project Agreement under the BARDA-funded Consortium Base Agreement. The company has not yet been provided with the specific reason for this suspension of work.
🚩 Red Flags
- Sudden suspension of a government-funded project (BARDA/ATI) without immediate explanation.
- Potential loss of critical R&D funding and momentum for the Phase 2b COVID-19 vaccine candidate trial.
- Uncertainty regarding whether this is a temporary pause or a permanent termination of the partnership.
📋 Key Facts
- Received written notification on August 5, 2025, from ATI to stop work on Project Agreement No. 01 (RRPV-24-04-NGVx-003).
- The project is part of the Rapid Response Partnership Vehicle funded by BARDA.
- The Company may continue follow-up for the 10,000-person cohort already dosed in its Phase 2b COVID-19 vaccine candidate trial.
- Approximately 50% of participants have been enrolled in the Trial as of August 5, 2025.
- The independent Data Safety Monitoring Board (DSMB) previously determined on July 14, 2025, that the study could proceed without modification.
Vaxart, Inc. has been delisted from the Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The company's common stock transitioned to trading on the OTCQX Best Market as of July 8, 2025.
🚩 Red Flags
- Delisting from a major exchange (Nasdaq) significantly reduces liquidity and institutional investor access.
- Failure to maintain minimum bid price indicates prolonged period of depressed share price.
- Transition to OTC markets often leads to increased volatility and wider bid-ask spreads.
📋 Key Facts
- Nasdaq issued a determination to delist the Company for failing to comply with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Trading on Nasdaq was suspended at the open of trading on July 8, 2025.
- The company's common stock has moved to the OTCQX Best Market under the symbol 'VXRT'.
- The Company appealed the delisting determination on July 3, 2025; Nasdaq trading remains suspended pending the appeal outcome.
Vaxart, Inc. has received a formal notice from Nasdaq to delist its common stock due to prolonged failure to meet the $1.00 minimum bid price requirement. Trading on the Nasdaq is expected to be suspended on July 8, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Imminent suspension of trading on a major exchange (July 8, 2025)
- Failure to regain compliance despite multiple extension periods (Dec 30, 2024 and June 30, 2025)
- Mention of continuing operating losses and accumulated deficit in forward-looking statements
- Uncertainty regarding capital funding and future capital needs
📋 Key Facts
- Nasdaq issued a Delisting Notice on July 1, 2025, due to ongoing non-compliance with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- Trading of VXRT common stock is scheduled to be suspended on the Nasdaq at the open of trading on July 8, 2025.
- The company plans to request a hearing before a Nasdaq Hearings Panel to stay the delisting process.
- A timely request for a hearing will not prevent the suspension of trading; securities remain suspended unless the Panel reinstates them.
- The company expects its stock to begin trading on the over-the-counter (OTC) market under the symbol 'VXRT' starting July 8, 2025.
- Vaxart has applied for trading on the OTCQX tier.
Vaxart, Inc. held its reconvened 2025 annual meeting where stockholders rejected a proposed reverse stock split (ranging from 1-for-5 to 1-for-50). Additionally, shareholders issued a non-binding vote against the compensation of named executive officers.
🚩 Red Flags
- Rejection of reverse stock split: Suggests shareholders may be opposing efforts to boost share price or maintain Nasdaq compliance.
- Say-on-Pay rejection: Shareholders voted against executive compensation packages, indicating significant dissatisfaction with management's pay structure.
- Forward-looking statement warnings highlight 'continuing operating losses,' 'accumulated deficit,' and 'future capital needs.'
📋 Key Facts
- Reconvened Annual Meeting held on June 13, 2025; quorum reached at 68.4% of outstanding shares.
- Proposal 2 (Reverse Stock Split): Rejected by stockholders (63,604,351 For vs. 91,897,715 Against).
- Proposal 4 (Executive Compensation): Non-binding advisory vote rejected (34,400,261 For vs. 71,451,726 Against).
- Six directors were elected to serve until the 2026 annual meeting.
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for FY2025.
- The company maintains an 'at the market' (ATM) facility but has not sold any shares under it as of June 13, 2025.
Vaxart, Inc. announced topline clinical trial data from a Phase 1 study comparing its second-generation oral norovirus vaccine constructs against its first-generation constructs.
🚩 Red Flags
- Clinical trial results are binary; failure to show superiority or non-inferiority could impact valuation significantly.
📋 Key Facts
- Announcement date: June 11, 2025
- Subject: Topline clinical trial data for Phase 1 study
- Focus: Second-generation oral pill norovirus vaccine vs. first-generation constructs
- Trial Type: Head-to-head comparison
Vaxart, Inc. adjourned its 2025 Annual Meeting of stockholders because it failed to secure sufficient votes for Proposal No. 2, which would authorize the Board to implement a reverse stock split. The meeting has been reconvened for June 13, 2025, to allow additional time for proxy solicitation.
🚩 Red Flags
- Failure to pass the reverse stock split authorization on the first attempt indicates significant shareholder opposition or lack of engagement regarding capital structure changes.
- Implicit need for a reverse stock split often suggests the company is facing Nasdaq minimum bid price requirements (delisting risk).
- Forward-looking statements explicitly mention 'continuing operating losses' and 'uncertainty of capital funding'.
📋 Key Facts
- The Annual Meeting was adjourned on June 2, 2025, due to insufficient votes for Proposal No. 2.
- Proposal No. 2 seeks authorization to amend the Certificate of Incorporation to allow a reverse stock split.
- Quorum was met with approximately 67.89% of outstanding common stock represented by proxies.
- The reconvened meeting is scheduled for June 13, 2025, at 8:30 a.m. PT via webcast.
- The record date for voting remains March 26, 2025.
Vaxart, Inc. issued a press release providing FAQ information regarding a proposed reverse stock split to be voted on at the upcoming 2025 Annual Meeting of Stockholders. The company also announced the adjournment of its Annual Meeting to June 2, 2025.
🚩 Red Flags
- Proposed reverse stock split (often used to maintain Nasdaq listing compliance or manage share price).
- Adjournment of Annual Meeting may indicate procedural delays or ongoing negotiations/uncertainties.
- High-risk signal for micro-cap investors as reverse splits often precede further dilution or reflect declining share value.
📋 Key Facts
- The Company is proposing a reverse stock split to be voted on by stockholders.
- The vote will take place at the 2025 Annual Meeting of Stockholders.
- The Annual Meeting has been adjourned from its original date to June 2, 2025, at 8:30 a.m. Pacific Time.
- The filing includes an FAQ press release intended for retail investors regarding the split.
Vaxart, Inc. announced the dosing of the first patient in a large-scale 10,000-participant Phase 2b clinical trial for its oral COVID-19 vaccine candidate.
📋 Key Facts
- Dosing of the first patient has commenced in the 10,000-participant portion of the ongoing Phase 2b clinical trial.
- The trial is evaluating an oral pill COVID-19 vaccine candidate.
- Announcement made via press release on May 27, 2025.
Vaxart, Inc. has adjourned its 2025 Annual Meeting of Stockholders to a reconvened date of June 2, 2025. The Board decided to postpone the vote on four proposals to allow stockholders additional time to cast their votes.
🚩 Red Flags
- Adjournment of an annual meeting can sometimes indicate difficulty in reaching the required threshold for specific shareholder proposals (e.g., director elections or auditor changes), though not explicitly stated here.
📋 Key Facts
- The 2025 Annual Meeting was convened on May 21, 2025.
- Proxies representing approximately 67% of outstanding common stock were submitted, establishing a quorum.
- Four proposals from the April 10, 2025 Proxy Statement were not voted upon due to adjournment.
- The reconvened Annual Meeting is scheduled for Monday, June 2, 2025, at 8:30 a.m. PT via live webcast.
- The record date remains March 26, 2025.
Vaxart, Inc. announced that its board of directors has approved resolutions to narrow the proposed range for an upcoming reverse stock split and intends to propose a reduction in authorized shares at a future meeting.
🚩 Red Flags
- Reverse stock split: Typically used by micro-cap companies to boost share price and avoid Nasdaq delisting due to minimum bid price requirements.
- Reduction of authorized shares: Often a precursor to restructuring or addressing capital structure issues related to heavy dilution.
📋 Key Facts
- Board approved narrowing the proposed reverse split range.
- The company proposes reducing authorized shares at a future meeting of stockholders.
- Resolutions are tied to the upcoming annual meeting of stockholders.
Vaxart, Inc. announced that it has received approval from BARDA to initiate dosing for a 10,000-participant Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This represents a significant regulatory milestone in the development of their primary vaccine platform.
📋 Key Facts
- Received approval from Biomedical Advanced Research and Development Authority (BARDA) to initiate dosing.
- The dosing is part of a 10,000-participant Phase 2b clinical trial.
- The candidate being tested is an oral pill COVID-19 vaccine.
- Approval comes via the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.
Vaxart, Inc. announced the resignation of CFO Phillip Lee and the appointment of Jeroen Grasman as the new Chief Financial Officer, effective May 19, 2025. The transition includes a brief period where the outgoing CFO will assist until June 1, 2025.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (though no disagreement was cited).
📋 Key Facts
- Phillip Lee resigned as CFO, Principal Accounting Officer, and Principal Financial Officer on May 12, 2025.
- Lee's resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Jeroen Grasman appointed as new CFO, effective May 19, 2025.
- Grasman previously served as CFO at AltruBio and VP of Finance/Operations at PACT Pharma.
- New CFO compensation includes a $435,000 base salary and target bonus of 40%.
- Equity incentives for new CFO include 1,000,000 stock options (48-month vest) and 350,000 RSUs.
Vaxart, Inc. filed an 8-K to furnish its first quarter 2025 financial results and a business update via press release. The filing is primarily for the purpose of disclosing quarterly earnings and operational progress.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 13, 2025
- Content: Financial results and business update (Exhibit 99.1)
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Vaxart, Inc. issued a press release containing FAQs regarding a proposed reverse stock split to be voted on at the upcoming 2025 Annual Meeting of Stockholders on May 21, 2025.
🚩 Red Flags
- Proposed reverse stock split (often used to combat delisting notices or improve share price perception).
- Upcoming stockholder vote creates immediate uncertainty regarding capital structure.
📋 Key Facts
- Proposed reverse stock split is subject to stockholder vote.
- The vote will occur at the 2025 Annual Meeting of Stockholders scheduled for Wednesday, May 21, 2025.
- Company issued a press release with FAQs to provide clarity on the proposed transaction.
Vaxart, Inc. issued a letter to stockholders and a press release regarding updates on vaccine programs and a proposed reverse stock split to be voted on at the 2025 Annual Meeting of Stockholders.
🚩 Red Flags
- Proposed reverse stock split (typically used to address Nasdaq minimum bid price requirements or improve share perception).
- Multiple items detected in a single filing (Item 7.01 and Item 9.01).
📋 Key Facts
- The company is proposing a reverse stock split to be voted on at the upcoming 2025 Annual Meeting of Stockholders.
- CEO Steven Lo issued a letter to stockholders regarding vaccine program developments.
- Filing includes updates on latest developments in Company's vaccine programs.
Vaxart, Inc. has received a 'stop work order lift' from Advanced Technology International (ATI), allowing the company to resume activities under its BARDA-funded Project Agreement. This follows a previous stop work order issued on February 21, 2025.
🚩 Red Flags
- Previous stop work order (February 21, 2025) indicates past instability in government-funded project execution.
- The company's ability to achieve milestones remains subject to ongoing discussions with BARDA regarding costs and regulatory pathways.
📋 Key Facts
- On April 24, 2025, ATI issued a 'Lift Notice' regarding the stop work order for Project Agreement No. 01 (RRPV-24-04-NGVx-003).
- The Company is permitted to resume incurring costs and communicating with the Government/ATI concerning the project award.
- BARDA has authorized the Company to proceed with screening for a 10,000 participant portion of the Trial.
- The Company intends to reactivate field sites and begin participant enrollment screening.
- Ongoing discussions are required regarding costs, timelines, and regulatory pathways.
Vaxart, Inc. has entered into an At-the-Market (ATM) offering agreement to sell up to $50 million in common stock through Citizens JMP Securities and B. Riley Securities.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap biotech companies to extend cash runway, which can signal upcoming liquidity needs.
📋 Key Facts
- Entered into ATM Offering Agreement on March 21, 2025.
- Aggregate offering amount: up to $50 million.
- Managers: Citizens JMP Securities, LLC and B. Riley Securities, Inc.
- Placement fee for Managers is up to 3% of the gross sale price.
- Shares will be sold via Nasdaq or privately negotiated transactions under an existing S-3 registration statement.
Vaxart, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's annual earnings release.
📋 Key Facts
- The report covers financial results for the year ended December 31, 2024.
- Results were announced via press release on March 20, 2025.
- Chief Financial Officer Phillip Lee signed the report.
Vaxart, Inc. announced the initiation of a Phase 1 clinical trial to evaluate its second-generation oral norovirus vaccine constructs against its first-generation constructs.
📋 Key Facts
- Initiation of a Phase 1, open-label, dose-ranging clinical trial.
- Trial objective: Head-to-head evaluation of second-generation vs. first-generation oral norovirus vaccine constructs.
- Announcement date: March 11, 2025.
Vaxart, Inc. received a stop-work order from Advanced Technology International (ATI) regarding its Project Agreement funded by BARDA. The order halts all work on the project for at least 90 days, except for protocol follow-up for an existing 400-person cohort.
🚩 Red Flags
- Suspension of government-funded research activity (BARDA/ATI).
- Uncertainty regarding the future of the Project Agreement (potential termination or extension of stop-work).
- Potential impact on clinical trial milestones and timelines.
📋 Key Facts
- Received written notification of stop-work orders from Advanced Technology International (ATI) on February 21, 2025.
- The order affects work under Project Agreement No. 01; RRPV-24-04-NGVx-003 dated June 13, 2024.
- ATI is the Consortium Management Firm for the Rapid Response Partnership Vehicle funded by BARDA (U.S. Dept. of Health and Human Services).
- The stop-work order is in effect for a minimum of 90 days from the date of notice.
- Within the 90-day window, ATI/the Government will decide to cancel, extend, or terminate the work.
- Work related to per protocol follow-up for the 400-person cohort is permitted to continue.
Vaxart, Inc. entered into a significant modification to its BARDA-funded project agreement with Advanced Technology International. The modification increases total trial funding by approximately $105.9 million and expands the clinical scope of its oral COVID-19 vaccine candidate study.
🚩 Red Flags
- Clinical trial outcomes are subject to significant risks and uncertainties; failure to meet milestones could impact funding/viability.
- The company continues to report ongoing operating losses (referenced in forward-looking statements).
📋 Key Facts
- Entered into Modification No. 5 to the ATI-RRPV Project Award Agreement on February 7, 2025.
- Total funding for the Trial increased by approximately $105.9 million, bringing the total allotted amount to ~$240.1 million.
- The trial will now compare the efficacy and safety of Vaxart's KP.2 oral vaccine candidate against an mRNA comparator.
- The expanded trial is designed to include 10,000 participants.
- Initial sentinel cohort data (30-day safety assessment) for the previous XBB candidate was recommended to proceed without modifications by the DSMB.
Vaxart, Inc. announced a change in its Board of Directors involving the appointment of Kevin Finney and Elaine J. Heron to various committees, alongside the resignation of Robert A. Yedid for personal reasons.
🚩 Red Flags
- None identified in this filing; resignation was explicitly stated as not being due to disagreements with company operations or policies.
📋 Key Facts
- Kevin Finney appointed to the Board, Audit Committee, and Nominating and Governance Committee, effective January 28, 2025.
- Robert A. Yedid resigned from the Board and all committees effective January 28, 2025; resignation was for personal reasons and not due to disagreements with the company.
- Elaine J. Heron, Ph.D. appointed to the Compensation Committee, effective January 28, 2025.
- Kevin Finney brings significant biotech experience, including leadership roles at Autobahn Therapeutics and Allergan.
Vaxart, Inc. announced that an independent Data Safety Monitoring Board (DSMB) recommended proceeding with its Phase 2b clinical trial for an oral pill COVID-19 vaccine candidate without modifications. The filing also includes general business updates regarding the company's COVID-19, norovirus, and influenza programs.
📋 Key Facts
- On January 13, 2025, a DSMB recommended proceeding with the Phase 2b clinical trial for the oral pill COVID-19 vaccine candidate without modifications.
- The clinical trial compares the oral vaccine against an approved mRNA vaccine comparator.
- Company provided business updates on COVID-19, norovirus, and influenza programs via press release dated January 14, 2025.
Vaxart, Inc. has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company is currently non-compliant but has been granted until June 30, 2025, to meet the standard or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement ($1.00 rule).
- Explicit mention of a potential reverse stock split to regain compliance.
- Ongoing non-compliance despite an initial 180-day grace period.
📋 Key Facts
- Nasdaq issued an Extension Letter on December 31, 2024.
- The company failed to regain compliance during the initial 180-day period ending December 30, 2024.
- A new compliance deadline has been set for June 30, 2025.
- Compliance requires a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days.
- The company explicitly mentioned considering a reverse stock split as a method to cure the deficiency.
Vaxart, Inc. has entered into Modification No. 4 to its Project Agreement with Advanced Technology International (a BARDA-funded entity). This modification significantly increases both the total funding ceiling and the currently allotted funds for their Phase 2b COVID-19 vaccine candidate trial.
🚩 Red Flags
- The filing includes standard forward-looking statement warnings regarding 'continuing operating losses,' which is a common risk factor for micro-cap biotech firms awaiting clinical milestones.
📋 Key Facts
- Modification No. 4 entered into on December 20, 2024.
- Total estimated funding ceiling increased to approximately $460.7 million (an increase of ~$4.6 million).
- Total amount currently allotted and available for payment increased to approximately $134.2 million (an increase of ~$37.7 million).
- Funds are designated for a Phase 2b comparative study of the oral pill XBB COVID-19 vaccine candidate against an FDA-approved mRNA comparator.
- Additional funding covers acquisition/distribution of clinical materials and site readiness for efficacy and safety portions of the trial.
Vaxart, Inc. announced the completion of enrollment for the sentinel cohort of its Phase 2b clinical trial for an oral COVID-19 vaccine candidate. The cohort consists of 404 participants randomized between the company's vaccine and an approved mRNA comparator.
📋 Key Facts
- Completion of enrollment for the sentinel cohort of a Phase 2b clinical trial was announced on December 2, 2024.
- The sentinel cohort comprises 404 total participants.
- At least 200 participants received Vaxart's oral COVID-19 vaccine candidate; approximately 200 received an approved mRNA comparator.
- The final dose for enrollment was administered on November 26, 2024.
Vaxart, Inc. filed an 8-K to furnish its third quarter 2024 financial results and a business update via press release. The filing serves as a formal announcement of the company's quarterly performance for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release titled 'Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results' as Exhibit 99.1.
Vaxart, Inc. has terminated its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc., effective October 18, 2024.
🚩 Red Flags
- Termination of an ATM (At-the-Market) program can sometimes indicate a company is moving away from dilutive financing, but in micro-caps, it may also signal the end of a primary source of immediate liquidity/cash runway extension.
📋 Key Facts
- Termination of the Sales Agreement is effective October 18, 2024.
- The Company will not incur any termination penalties for ending the agreement.
- Since September 15, 2021, the company has sold 17,501,561 shares via this agreement.
- Aggregate gross proceeds from these sales totaled approximately $28.6 million.
- The Company stated it does not intend to issue or sell any additional shares under this specific agreement prior to termination.
Vaxart, Inc. entered into a modification to its BARDA-funded Project Agreement, significantly increasing both the total funding ceiling and the currently allotted funds for its Phase 2b clinical trial of an oral COVID-19 vaccine candidate.
🚩 Red Flags
- The filing includes forward-looking statement warnings regarding the company's continuing operating losses.
📋 Key Facts
- Entered into Modification No. 3 to the ATI-RRPV Project Award Agreement on September 27, 2024.
- Total estimated funding ceiling increased by ~$3.2 million to approximately $456.1 million.
- Currently allotted funding for the Trial increased by ~$30.8 million to approximately $96.5 million.
- Funding includes provisions for manufacturing a vaccine construct targeting the KP.2 strain.
- BARDA authorized the commencement of the 'sentinel portion' of the Phase 2b trial involving a cohort of 400 individuals comparing Vaxart's XBB vaccine against an mRNA comparator.
Vaxart, Inc. filed an 8-K to furnish its second quarter 2024 financial results and a business update via press release. The filing is a routine disclosure of quarterly earnings and operational progress.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the business update and financial results
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability
Vaxart, Inc. received a notice from Nasdaq stating it is non-compliant with the $1.00 minimum bid price requirement. The company has 180 days to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential necessity of a reverse stock split to regain compliance
📋 Key Facts
- Received written notice from Nasdaq on July 2, 2024.
- Non-compliance is due to failure to maintain a $1.00 minimum bid price for the 30 consecutive business days between May 17, 2024, and July 1, 2024.
- The company has an initial 180-day period to regain compliance, expiring December 30, 2024.
- Compliance can be achieved if the stock closes at $1.00 or higher for 10 consecutive business days.
- A second 180-day extension may be available if the company intends to effect a reverse stock split to cure the deficiency.
This is an amendment to a previous 8-K filing intended to correct a calculation error regarding the voting results of Proposal No. 2 from the 2024 Annual Meeting. The correction does not change the outcome of the vote, which was for the increase in authorized common stock.
🚩 Red Flags
- Calculation error in official voting results reported to the SEC (though outcome remains unchanged).
📋 Key Facts
- The filing is an amendment (8-K/A) to a report filed on June 13, 2024.
- Proposal No. 2 involved increasing authorized common stock from 250,000,000 to 350,000,000 shares.
- Corrected voting results for Proposal 2: 35,936,013 For; 21,134,398 Against; 491,543 Abstentions; 47,701,989 Broker Non-Votes.
- The correction was necessitated by a calculation error identified in the results provided by an outside voting tabulation firm.
Vaxart, Inc. filed an 8-K to furnish a press release containing a business update issued on June 17, 2024. The filing is made under Item 7.01 (Regulation FD Disclosure) and does not contain material financial changes or structural shifts in this specific document.
📋 Key Facts
- The company issued a press release providing a business update on June 17, 2024.
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
- The information provided is furnished but not 'filed' for purposes of Section 18 liability.
Vaxart, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. to conduct a registered direct offering of 50,000,000 shares at $0.80 per share. The offering aims to raise approximately $40 million in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of 50 million new shares will significantly dilute existing shareholders.
- Low share price: The $0.80 pricing is characteristic of micro-cap companies facing liquidity needs or struggling to maintain higher valuations.
📋 Key Facts
- Offering size: 50,000,000 shares of common stock.
- Price per share: $0.80.
- Expected gross proceeds: $40,000,000 (before discounts and expenses).
- Underwriter: Oppenheimer & Co. Inc.
- Closing date expected: June 17, 2024.
- Offering type: Registered direct offering pursuant to an existing S-3 registration statement.
Vaxart, Inc. entered into a Project Agreement with Advanced Technology International (funded by BARDA) to conduct a Phase 2b comparative study of its oral XBB COVID-19 vaccine candidate against an FDA-approved mRNA vaccine. The agreement provides for potential total funding of up to $453 million.
🚩 Red Flags
- Funding is contingent upon BARDA's decision to continue funding after the initial phase.
- Clinical trial success is not guaranteed; results depend on achieving primary endpoints regarding relative efficacy and safety.
📋 Key Facts
- Entered into Project Agreement with Advanced Technology International (BARDA-funded) on June 13, 2024.
- Total potential funding: Up to approximately $453 million.
- Initial award amount: Up to ~$65.7 million ($64.7M fixed fee + cost reimbursement).
- Phase 2b study design: Double-blind, multi-center, randomized, comparator-controlled trial involving ~10,000 healthy adults.
- Trial objective: Evaluate relative efficacy, safety, and immunogenicity of oral XBB vaccine vs. approved mRNA injectable.
- Study enrollment details: 5,000 participants receiving Vaxart candidate; 5,000 receiving mRNA comparator.
Vaxart, Inc. reported the results of its 2024 annual meeting of stockholders held on June 11, 2024. Shareholders approved several key measures including an increase in authorized shares and amendments to equity incentive plans.
🚩 Red Flags
- Significant increase in authorized shares (100 million additional shares) can lead to future dilution if used for capital raises.
📋 Key Facts
- Stockholders increased authorized common stock from 250,000,000 to 350,000,000 shares (Proposal 2).
- The 2019 Equity Incentive Plan was amended to increase reserved shares by 15,000,000 to a total of 43,900,000 (Proposal 3).
- The 2022 Employee Stock Purchase Plan was amended to increase reserved shares by 1,800,000 to a total of 3,600,000 (Proposal 4).
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for FY2024 (Proposal 5).
- All six proposals presented at the annual meeting were approved by stockholders.
Vaxart, Inc. filed an 8-K to furnish its first quarter 2024 financial results and a business update via press release. The filing is primarily for compliance regarding the disclosure of quarterly earnings.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release titled 'Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results' as Exhibit 99.1.
- Information is furnished under Item 2.02 but not considered 'filed' for purposes of Section 18 liability.
Vaxart, Inc. announced the completion of topline analysis for its Phase 1 clinical trial regarding an oral pill bivalent norovirus vaccine candidate.
📋 Key Facts
- Completed topline analysis for Phase 1 clinical trial on April 30, 2024.
- The trial evaluated an oral pill bivalent norovirus vaccine candidate.
- Results were communicated via a press release issued on the same date.
Vaxart, Inc. filed an 8-K to announce its full year 2023 financial results and provide a business update via press release.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the business update and financial results.
- Signed by Michael J. Finney, Ph.D., Interim CEO and Chair of the Board.
Vaxart, Inc. has appointed Steven Lo as the new Chief Executive Officer, President, and principal executive officer, effective March 18, 2024. Dr. Michael J. Finney will transition from his interim CEO role to serve as Chair of the Board.
🚩 Red Flags
- Leadership transition in a micro-cap biotech can often signal shifts in strategic direction or internal restructuring.
📋 Key Facts
- Steven Lo appointed as CEO, President, and principal executive officer effective March 18, 2024.
- Dr. Michael J. Finney steps down as Interim CEO but remains as Chair of the Board.
- Mr. Lo's compensation includes a $600,000 annual base salary and a target bonus of up to 50% of base salary.
- Equity incentives for Mr. Lo include an option for 1,000,000 shares (48-month vesting) and 250,000 RSUs (vesting over 4 years).
- Mr. Lo brings significant biotech experience from Valitor, Inc., Zosano Pharma, Puma Biotechnology, and Genentech.
Vaxart, Inc. adopted the 2024 Inducement Award Plan to facilitate the hiring of new employees and re-hiring of former staff through equity awards. The plan reserves 3,000,000 shares of common stock for issuance under this program.
🚩 Red Flags
- Potential dilution of existing shareholders via the reservation of 3,000,000 new shares.
📋 Key Facts
- Board adopted the Vaxart, Inc. 2024 Inducement Award Plan on February 27, 2024.
- The plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).
- Reserved 3,000,000 shares of common stock for issuance under the new plan.
- Awards are limited to new hires or employees being rehired after a bona fide interruption in employment.
- The plan includes restricted stock units (RSUs) and other stock-based awards; however, incentive stock options may not be issued under this specific 2024 plan.
Vaxart, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement. This follows a period of non-compliance where the stock was at risk of delisting.
🚩 Red Flags
- Historical delisting risk (though currently resolved)
📋 Key Facts
- The Company received a letter from Nasdaq Listing Qualifications Staff on February 14, 2024.
- Compliance regained for Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- Compliance was achieved because the common stock closed at $1.00 or more per share for ten consecutive business days.
Vaxart, Inc. filed an amendment to its previous 8-K to disclose the finalized separation agreement for former President and CEO Andrei Floroiu. The agreement includes various severance benefits in exchange for a release of claims and restrictive covenants.
🚩 Red Flags
- CEO departure often signals internal transition or strategic shifts in micro-cap biotech firms.
- Significant cash outflow required for severance benefits (salary + health insurance + bonus).
📋 Key Facts
- Andrei Floroiu resigned as President, CEO, and Board Member (effective date of original report: Jan 15, 2024).
- Separation Agreement finalized on January 31, 2024.
- Severance includes 12 months of continued base salary and subsidized health insurance premiums.
- Includes potential 2023 bonus payout if applicable.
- Accelerated vesting of equity awards through September 30, 2024.
- Two-year window provided to exercise vested stock options.
- Agreement includes non-competition, non-solicitation, and non-disparagement covenants.
Vaxart, Inc. has received a second 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for 10 consecutive trading days by July 15, 2024, or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq minimum bid price requirement.
- Potential for a reverse stock split to artificially inflate share price.
- Ongoing failure to maintain minimum listing standards despite previous extension.
📋 Key Facts
- Nasdaq granted an extension until July 15, 2024, to cure the Bid Price Requirement deficiency.
- The company failed to regain compliance during the initial 180-day period (which expired January 17, 2024).
- Compliance requires a minimum closing bid price of $1.00 for at least 10 consecutive trading days.
- The company has indicated it is considering a reverse stock split as a potential method to regain compliance.
- Vaxart received an award from the U.S. Department of Health and Human Services on January 19, 2024, to fund clinical study preparation.
Vaxart, Inc. entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. to raise approximately $10 million through the issuance of common stock.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 15 million new shares.
- The offering price of $0.65 per share is relatively low, which may indicate a need for immediate liquidity in a micro-cap environment.
📋 Key Facts
- The Company will issue 15,384,615 shares of common stock to RA Capital Healthcare Fund, L.P.
- The offering price is set at $0.65 per share.
- Total transaction value is approximately $10 million.
- The offering is being conducted under a previously declared effective shelf registration statement (Form S-3) from May 5, 2023.
- Closing is expected on or about January 18, 2024.
Vaxart, Inc. announced the resignation of its President and CEO, Andrei Floroiu, effective January 15, 2024, alongside the appointment of Board Chair Dr. Michael J. Finney as Interim CEO. Simultaneously, the company secured a significant $9.27 million contract from the U.S. Department of Health and Human Services (ASPR) to support clinical trial planning for its XBB vaccine candidate.
🚩 Red Flags
- Sudden departure of the President and Chief Executive Officer (Officer Departure).
- Multiple material events in a single filing (Material Agreement + Officer Departure) increases volatility risk.
- The company mentions 'continuing operating losses' in its forward-looking statements disclaimer.
📋 Key Facts
- CEO Andrei Floroiu resigned as President, CEO, and Board Member on January 15, 2024.
- Dr. Michael J. Finney appointed Interim CEO effective January 16, 2024; he will receive a base salary of $595,000/year plus a 50% target bonus.
- Awarded an ASPR Contract (75A50124C00002) valued at $9,271,193.00 for Phase 2b clinical trial planning of the XBB vaccine candidate.
- David Wheadon, M.D. appointed as Lead Director with a $25,000 annual cash retainer.
- The company is conducting a search for a permanent CEO successor.